MUMBAI, India, Sept. 14 -- Intellectual Property India has published a patent application (202617086168 A) filed by Boehringer Ingelheim International Gmbh on July 14, 2026, for Cancer Combination Therapy Using Zongertinib And A Kras Inhibitor.
Inventors include Waizenegger, Irene; Augsten, Martin; Baum, Anke; Gerlach, Daniel; Lipp, Jesse; Lyu, Hengyu; and Savarese, Fabio.
The application for the patent was published on September 11, 2026, under issue no. 37/2026.
Abstract: The present invention refers to the combination of the HER2 tyrosine kinase zongertinib with a KRAS G12C inhibitor. The combination of the invention is useful for the treatment and/or prevention of oncological and/or hyperproliferative diseases, such as cancer. Accord...